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Abstract:
Background:
Systemic Lupus Erythematosus (SLE) is a systemic autoimmune disease characterised by abnormal activation of the immune system,
chronic inflammation and organ damage. Lupus patients are more prone to be vitamin D deficient. However, current evidence is not
conclusive with regards to the role played by vitamin D in SLE development, progression, and clinical manifestations.
Objective:
Here, we will summarise the current knowledge about vitamin D deficiency prevalence, risk factors, molecular effects, and potential
pathogenic role in SLE. We will focus on the link between vitamin D deficiency and lupus clinical manifestations, and on the clinical
trials assessing the effects of vitamin D supplementation in SLE.
Method:
A detailed literature search was performed exploiting the available databases, using “vitamin D and lupus/SLE” as keywords. The
relevant interventional trials published over the last decade have been considered and the results are reported here.
Conclusion:
Several immune cells express vitamin D receptors. Thus, an immunomodulatory role for vitamin D in lupus is plausible. Numerous
observational studies have investigated the relationship between vitamin D levels and clinical/serological manifestations of SLE with
contrasting results. Negative correlations between vitamin D levels and disease activity, fatigue, renal and cardiovascular disease,
and  anti-dsDNA  titres  have  been  described  but  not  conclusively  accepted.  In  experimental  models  of  lupus,  vitamin  D
supplementation can improve the disease. Interventional trials have assessed the potential therapeutic value of vitamin D in SLE, but
further larger studies are needed.
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1. INTRODUCTION
Systemic Lupus Erythematosus (SLE) is a chronic multifactorial systemic autoimmune disease affecting women
more frequently than men, and with a peak of incidence in childbearing age [1]. Abnormal activation of the immune
system, chronic inflammation, and tissue damage constitute the hallmark of the disease. SLE clinical manifestations are
widely  heterogeneous,  ranging  from  mild  symptoms  of  fatigue  and  oral  ulcerations  to  life-threatening  renal  and
neurologic disease complications. Typically, the disease fluctuates between clinical flares and quiescence; however,
recurrent  flares  may  ultimately  lead  to  irreversible  organ  damage  [2].  The  aetiology  of  lupus  has  not  been  fully
elucidated  yet,  but  it  has  been  associated  with  a  variety  of  factors  including  genetic  and  epigenetic  predisposition,
female sex hormones, and environmental factors such as infections, Ultraviolet (UV) exposition and cigarette smoking
[3]. Even if remarkable advances have been made in unravelling lupus pathogenesis, this remains not entirely defined.
Increased production of type I interferon (IFN) by the innate immune cells, activation of T helper (Th) 1/Th17 with
lowered interleukin (IL) 4 production [4], defects in the clearance of apoptotic debris, persistence of autoantigens, and
release  of  autoantibodies  are  among  the  crucial  events  leading  to  SLE  development.  Eventually,  damage  to  target
organs and tissues is mediated by Immune Complexes (IC) deposition and complement activation. To date, treatment of
lupus  mostly  depends  on  immunosuppressive  agents;  nonetheless,  the  complexity  of  the  pathogenic  mechanisms
involved might offer several further options for immunomodulatory therap in the future [5].
Vitamin  D  is  a  steroid  hormone,  primarily  known  for  its  role  in  the  regulation  of  the  calcium and  phosphorus
homeostasis and bone protection but, more recently, a potential novel role for vitamin D as a modulator of the immune
system  has  been  described  too.  Once  activated,  vitamin  D  can  exert  its  activity  by  binding  Vitamin  D  Receptors
(VDRs). In human, VDRs are widely expressed including numerous immune cells, suggesting that vitamin D may play
an essential function in controlling immune system responses. This finding has encouraged several studies aiming at
elucidating the immunomodulatory properties of the vitamin D/VDR axis [6, 7]. Defective signalling surely determines
bone health and development’s issues, but it could also associate with increased risk of multiple chronic diseases like
autoimmune conditions, infectious diseases, and cancer [8]. In 1995, Muller et al. firstly described the link between low
vitamin D levels  and lupus [9];  since then,  several  subsequent  reports  confirmed a  higher  prevalence of  vitamin D
deficiency amongst SLE patients compared to the general population, often also observing a correlation with the disease
severity [10 - 16].
Whether or not vitamin D deficiency could ultimately contribute to SLE onset, progression or clinical phenotype is
still  an  unanswered  question.  Clinical  trials  assessing  the  therapeutic  efficacy  of  vitamin  D  supplementation  as  an
immunomodulatory agent in SLE have given contrasting results, but more extensive studies will hopefully help to shed
light on this topic.
Here, we will summarise the current knowledge about vitamin D deficiency prevalence, risk factors and possible
pathogenic role in SLE; also, critical molecular studies aiming at an in-depth characterisation of the immunomodulatory
effects of vitamin D will be reviewed. Finally, we will focus on the link between vitamin D deficiency and clinical
aspects of SLE and will recapitulate the results of the clinical trials assessing the effects of vitamin D supplementation
in SLE.
2. VITAMIN D METABOLISM
Vitamin D is a steroid hormone essential for calcium metabolism and bone protection. It is partly obtained from the
diet  (vitamin  D2  or  ergocalciferol),  but  it  predominantly  derives  from  the  photo-conversion  of  the  7-
dehydroxycholesterol into vitamin D3 (or cholecalciferol) occurring in the skin in response to UV radiation [17]. Both
ergocalciferol  and cholecalciferol  need to  undergo chemical  modifications to  be biologically  active.  The activation
requires two steps: i) in the liver, cytochrome p450 (CYP) hydroxylases, particularly CYP2R1, convert cholecalciferol
into 25-dihydroxy-vitamin D3 [25(OH)D3]; ii) in the kidney, the 1α-hydroxylase CYP27B1 generates the active form
1,25-dihydroxy-vitamin D3 [1,25(OH)2D3], or calcitriol, which is around 10 times more effective than the 25(OH)D3.
To maintain adequate levels of calcitriol, the 24-hydroxylase (CYP24A1) acts as a negative feedback on the vitamin D
activation  by  hydroxylating  both  the  25(OH)D3  and  the  1,25(OH)2D3  to  generate  less  active  molecules.  The
Parathyroid  Hormone  (PTH)  is  capable  of  modulating  the  equilibrium  between  the  “activator”  CYP27B1  and  the
“inhibitor” CYP24A1, shifting the system towards calcitriol formation. Low concentration of calcium in the serum up-
regulates  PTH;  conversely,  high  levels  of  calcitriol  can  down-regulate  and suppress  it  [18,  19].  More  recently,  the
phosphaturic  hormone  fibroblast  growth  factor  23  (FGF23)  emerged  as  a  negative  regulator  of  the  1,25(OH)2D3
generation [20].
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Historically, 1,25(OH)2D3 was known for its ability to enable the absorption of calcium in the gastrointestinal tract
to control the calcium homeostasis. Constant low levels of calcitriol impair intake of calcium from the intestine and
favour the mobilisation of calcium from the bone ultimately leading to pathologies such as osteomalacia, osteoporosis
and rickets [21, 22]. 1,25(OH)2D3 acts by binding its receptor VDR and mediating its conformational modification;
VDR works as a transcription factor regulating the DNA-expression of the Vitamin D Response Elements (VDREs)
[23].  Of  notable  importance  in  the  context  of  autoimmune  diseases  as  SLE  the  effect  of  the  chronic  use  of
corticosteroids,  which  can  increment  the  activity  of  the  calcitriol-inhibitor  CYP24A1 while  lowering  the  intestinal
absorption of calcium [24, 25].
3. PREVALENCE AND RISK FACTORS FOR VITAMIN D DEFICIENCY IN SLE
3.1. Vitamin D Deficiency Definition
In current practice, the vitamin D status is evaluated by measuring the serum concentration of 25(OH)D3, a mirror
of the most abundant pool sequestred in adipose tissue and muscles [26]. Analytical variability and discrepancies in
epidemiologic  studies  raise  the  controversy  on  a  universally  accepted  definition  of  vitamin  D  deficiency.  Several
techniques  ranging  from  liquid  chromatography  and  chemiluminescence  to  immunoassay  have  been  developed,
resulting in an intra-sample variability of up to 20% [27]. So far, liquid chromatography is probably the most reliable
methodology  as  it  is  not  influenced  by  the  presence  of  other  vitamin  D  species  and  metabolites  [28].  In  2010,  an
international  collaborative  venture  was  launched  by  the  National  Institutes  of  Health  aiming  at  promoting
standardisation of the laboratory measurement of 25(OH)D3 and defining the appropriate concentration of plasmatic
vitamin D [29]. Several international health and scientific organisations have approached this issue including the World
Health  Organization  (WHO),  the  Institute  of  Medicine  (IOM)  and  the  Endocrine  Society  (ES),  reaching  different
conclusions regarding the desirable level of circulating 25(OH)D3.
The ES sets the threshold to 30 ng/mL while the IOM to 20 ng/mL, discrepancy partially justified by the different
target population considered. Nevertheless, both measures seem poorly representative for non-white ethnicities [27, 30,
31]. Despite using different criteria, both the ES and the IOM based their statements on a systematic review of the
literature  focusing  mainly  on  ‘skeletal’  outcomes  such  as  PHT  inflexion  point,  calcium  absorption,  osteomalacia,
rickets, Bone Mineral Density (BMD), and fractures [27, 30, 31]. In the absence of a universally accepted definition,
most of the studies currently use a cut-off of 30 ng/mL to designate vitamin D insufficiency, and values under 20 ng/mL
for vitamin D deficiency [17, 30, 32, 33]. Further studies focusing on non-musculoskeletal outcomes and representative
of a more varied genetic background/ethnicity remain to be carried out [28].
3.2. Prevalence Of Hypovitaminosis D In Disease
Vitamin D deficiency is common in the general population and, as expected, its prevalence increases with higher
latitudes [17]. Nonetheless, the still significant frequency of vitamin D deficiency in countries with high sun exposure
suggests that other factors other than UV radiation influence the levels of 25(OH)D3, e.g. genetics, diet, cultural habits
and clothing [17, 34]. A growing number of preclinical works is shedding light on the pleiotropic effects of vitamin D
on  virtually  any  cells.  Thus,  it  is  not  surprising  that  a  plethora  of  observational  studies  described  altered  levels  of
25(OH)D3 in multiple conditions such as diabetes [35], atherosclerosis,  cancer, and autoimmunity. Indeed, in most
case-control  studies  on  autoimmune  diseases  including  SLE,  patients  had  persistently  lower  vitamin  D  levels  than
controls [17, 36 - 39]. The inclusion of healthy controls as comparator group is mandatory to rightly interpret data on
vitamin D deficiency/insufficiency because of its broad diffusion and the high variability of its prevalence worldwide.
Among 14 controlled studies reviewed by Reynolds and Bruce in 2017 [40], 12 of them showed significantly lower
levels of serum vitamin D in SLE, while only two failed to detect different average values between cases and controls
[11,  41].  Hence,  despite  a  prevailing  consensus  that  SLE  patients  have  significantly  lower  levels  of  vitamin  D,
variations  in  assay  techniques,  cut-off  values,  seasonality,  ethnicity,  age,  sex,  disease  duration  and  latitude,  all
contribute to making the frequency of vitamin D deficiency/insufficiency challenging to compare between different
studies. Overall, the rate of vitamin D deficiency/insufficiency considerably diverge across multiple cohorts, ranging
from 8 to 30% [10, 42 - 47].
3.3. Risk Factors For Vitamin D Deficiency
Recurrently finding lower vitamin D levels in SLE patients raises a burning question still far to be answered: is
vitamin D deficit a contributing factor to SLE development? Or, is it merely a consequence of the disease? Several
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plausible  hypotheses  about  this  relationship  have  been  advanced.  Reduced UV exposure  is  indeed  frequent  in  SLE
patients. Active sun avoidance and use of high factor sunblock are recommended by clinicians worldwide due to the
photosensitivity  typical  of  the  disease  [14,  48].  Additionally,  it  is  conceivable  that  symptoms  such  as  fatigue  and
polyarthralgia may limit the outdoor activity of SLE patient impacting on the UV exposure and vitamin D metabolism.
However, a recent study by Shoenfield et al. analysing CYP24A1 polymorphisms showed that the photosensitivity and
the sun exposure behaviour did not correlate with vitamin D levels, suggesting that the genetic background is a stronger
driver of vitamin D status [49, 50]. Renal involvement typical of SLE may also affect the vitamin D metabolism by
impairing its  1-hydroxylation occurring in  kidneys.  Epidemiological  studies  identified nephritis  as  one of  the  most
influential predictors of vitamin D deficiency [14, 42, 51]. Medications could, in theory, participate to reducing the
levels of vitamin D. Corticosteroids, for instance, may lower the intestinal calcium absorption and increase vitamin D
catabolism; therefore, when prescribed for SLE treatment, steroids may contribute to vitamin D deficiency [51 - 53].
Though, even if plausible, this cannot fully explain the low level of vitamin D found in SLE patients, especially before
the diagnosis when still  steroids-naïve [48, 49]. Genetic variations  also participate in regulating the absorption and
metabolism of 25(OH)D3 [54]. For instance, intronic polymorphisms of the regulatory region of the gene encoding the
negative  regulator  CYP24A1 [18]  have  been  associated  with  SLE:  in  subjects  with  increased  genetic  risk  for  SLE
development, the presence of two copies of the minor allele is able to increase 25(OH)D3 levels reducing the risk of
having the disease [50].
Finally, 25(OH)D3 may also act as a negative acute phase reactant, dropping in consequence of acute or chronic
inflammation. This relationship has been recently confirmed by a meta-analysis demonstrating that serum 25(OH)D3
levels decrease following traumatic events as orthopaedic surgery and acute pancreatitis and inversely correlate with C-
Reactive Protein values [55].
4. ROLE OF VITAMIN D IN THE IMMUNE SYSTEM REGULATION
As previously mentioned, the discovery of the expression of VDRs by a plethora of innate and adaptive immune
cells [56 - 58] allowed to hypothesise a role for vitamin D in the immune system regulation and, potentially, in the
pathogenesis/progression  of  conditions  characterised  by  an  impaired  functioning  of  the  immune  response.  In  vitro
studies have shown in multiple cell types that the vitamin D/VDR axis has important and broad immunomodulatory
properties,  overall  mediating  a  negative  regulation  of  several  immunological  abnormalities  lupus-related.  In  the
adaptive system, 1,25(OH)2D3 can decrease the proliferation of B cells by up-regulating their apoptosis, inhibit the B
cells-to-plasma cells  differentiation and the immunoglobulin (Ig)  class switching,  and limit  the production of auto-
antibodies including the anti-double strand (ds) DNA [59 - 61]. Since B lymphocytes are CYP27B1-expressing cells, an
autocrine regulation of the response to calcitriol seems likely [61, 62]. Similarly, also in T cells the main effect of the
vitamin D stimulation is a modulation of their activation. Numerous T cell populations like Th CD4+ and CD8+ cells
express the VDR and can be targeted by vitamin D [57], and the VDR expression seems to be induced in response to an
initial  T-Cell  Receptor  (TCR) signalling  [63].  On the  one  hand,  vitamin D negatively  regulates  the  release  of  pro-
inflammatory cytokines, e.g. IL-17A and IL-12p70, and reduces the relative percentage of the Th17 subset [64, 65].
Contrariwise, it raises, at least temporarily, the number of the T-regulatory (Treg) cells and the expression of Treg-
specific markers [66]. Among the innate immune cells, both DCs and monocytes/macrophages express the VDR and the
activating  enzyme CYP27B1 [67].  In  monocytes,  treatment  with  1,25(OH)2D3 decreases  MHCII  and  CD80/CD86
expression  [68],  inhibits  monocytes  differentiation  [69]  and  limits  the  pro-inflammatory  effects  secondary  to  the
activation of Toll-Like-Receptors (TLR), e.g. TLR 9 [70]. Vitamin D-treated macrophages show an M2-preferential
phenotype [71], characterised by reduced production of Tumor Necrosis Factor (TNF)-α, IL-1β, IL-6, and nitric oxide
but  increased  IL-10  [72],  and  have  a  limited  ability  to  activate  T  cells  [73].  Vitamin  D can  modulate  the  immune
response also by inhibiting the maturation of DCs [69]: these immature and tolerogenic DCs have immunomodulatory
properties and are able to promote Treg differentiation while restraining the proliferation of inflammatory T cells [74 -
76]. To note, when monocyte-derived DCs from lupus patients were treated with dexamethasone in combination with
vitamin D3 they became able to promote IL10-expressing-Treg and to inhibit the pro-inflammatory T cell phenotype
[77]. Neutrophils express VDRs too [78]; studies in SLE showed that, when bound by their ligand 1,25(OH)2D3, the
activated VDR mediates an overall improvement of the endothelial damage secondary to the decreased generation of
Neutrophils-Extracellular-Traps (NET) [79]. Some of the vitamin D effects observed in vitro were replicated in animal
models of lupus, for instance, its ability to favour Treg differentiation and Foxp3 expression [80], to reduce IL-17/23,
IFN-gamma and IL-6,  and to  decrease  the  titre  of  anti-dsDNA antibodies  [80,  81].  A potential  therapeutic  role  for
vitamin D in improving clinical manifestations of lupus was hypothesised based on the decreased severity of the disease
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observed  in  MRL/1  mice  treated  with  1,25(OH)2D3  [82].  Immunomodulatory  properties  of  vitamin  D  were  also
confirmed in both controls and SLE patients treated with vitamin D supplementation; in healthy volunteers receiving
12-weeks of oral cholecalciferol supplementation (140000 IU/month) the number of Treg cells significantly increased
[83]. Also, the pro-inflammatory cytokines production by cells isolated from vitamin D-deficient but otherwise healthy
participants was reduced in subjects who corrected vitamin D levels following supplementation [84]. The chance that
vitamin  D  could  act  as  an  immunomodulatory  therapeutic  agent  prompted  numerous  studies  assessing  the  role  of
vitamin D supplements in improving the immune and clinical responses in SLE. As it will be discussed afterwards,
cholecalciferol administration to lupus patients seems to mediate a shift of the ratio between Th1/Th17 effector cells
and Treg in favour of the latter [85 - 87], meanwhile decreasing the number of memory B cells and the production of
anti-dsDNA antibodies [85 - 87]. Consistently, a negative correlation between 25(OH)D3 levels and the presence of
anti-dsDNA antibodies  was  repeatedly  observed  [11,  90].  Finally,  some  [11,  88],  however  not  all  the  studies  [91]
showed a negative correlation between the serum vitamin D values and the IFN signature in lupus patients.
5. DOES HYPOVITAMINOSIS D PLAY A ROLE IN SLE DEVELOPMENT?
As discussed above, although the high prevalence of vitamin D deficiency in lupus has been broadly demonstrated
and accepted, its potential role in the development, progression and clinical manifestations of the disease is still under
investigation.  Several  studies tried to establish a pathogenic function for impaired vitamin D levels in autoimmune
diseases,  though  this  sounds  scientifically  challenging.  The  body  of  evidence  on  the  immunological  and  non-
immunological  disease-associated  pathways  potentially  controlled  by  vitamin  D  is  exponentially  growing,  but
conclusive mechanistic correlations in human are elusive and hard to prove, particularly because most of the available
data come from observational studies. Interestingly, significant lower vitamin D levels have been observed in subjects
with anti-nuclear  antibodies  (ANA) positivity  but  not  clinically  proven SLE, hence suggesting that  a  breach of  the
immune  tolerance  may be  more  common in  vitamin  D deficient  subjects  [88].  A retrospective  analysis  of  hospital
admissions records in England related to diseases associated with vitamin D deficiency, including osteomalacia and
rickets, revealed an increased future risk of developing immune-mediated conditions such as SLE, Rheumatoid Arthritis
(RA)  and  systemic  sclerosis  in  these  patients  [92].  However,  due  to  the  intrinsic  limitations  of  this  kind  of  study,
confounders and reverse causality cannot be ruled out [92]. More recently, vitamin D deficiency in high-risk subjects
(SLE siblings), along with CYP24A1 polymorphisms, have been associated with higher prevalence of SLE onset within
a follow-up period of 6 years [50]. In keeping with this, patients who progress from an undifferentiated Connective
Tissue Disease (CTD) to a defined CTD seem more likely to have lower vitamin D levels than the non-progressors [93].
As it will be discussed later in this manuscript, experimental vitamin D administration (or deprivation) in animal
models of SLE offers some insight on this topic. It seems indeed that the administration of 1,25(OH)2D3 to MRL/1
mice, a model of spontaneous SLE, prevents dermatological lesions such as alopecia and ear necrosis [82], and reduces
the severity of proteinuria and arthritis, overall increasing the lifespan [94].
5.1. Vitamin D Receptor (VDR) Gene Polymorphisms Correlate With Risk of SLE
Genetics may further help to elucidate the link between vitamin D and SLE. Some of the numerous polymorphisms
located within the VDR genes have been indeed associated with a higher risk of developing SLE in multiple studies.
Meta-analyses  of  genetic  studies  confirmed  the  correlation  for  some  of  the  SNPs  in  VDR  in  Asians  but  not  in
Caucasians.  Among  those,  the  most  extensively  studied  mutations  are  TaqI(rs731236),  BsmI(rs1544410),
ApaI(rs7975232), and FokI(rs2228570) [95]. More specifically, the B allele in the VDR BsmI associates with a raised
risk of SLE in the general population, with the strongest correlation in Asians and a lack of association in Caucasians.
The association between the  VDR  FokI  and the  risk  of  SLE was  confirmed too;  though,  a  subsequent  sub-analysis
performed categorising patients for ethnicity again failed to identify any correlation in Caucasians. Data coming from
the three genetic studies about ApaI revealed an association only in patients of African origin, and they should be taken
anyway with some caution because of the limited sample size [96, 97]
6.  CORRELATION  BETWEEN  VITAMIN  D  DEFICIENCY  AND  CLINICAL  AND  SEROLOGICAL
MANIFESTATIONS IN SLE
In  keeping  with  the  above-described  modulatory  properties  of  25(OH)D3  on  the  immune  system  cells,  a
considerable effort has been made over the last decades to investigate the association between vitamin D levels and
lupus severity, disease progression, immunologic status, and comorbidities. To date, even if numerous studies have
been published worldwide over the last decade (Table 1), data in this field are not as yet conclusive: while some studies
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reported an inverse correlation between vitamin D levels and lupus disease activity, disease flares, Cardiovascular (CV)
involvement, renal disease, fatigue, and anti-dsDNA titre, these results were not constantly replicated. The interest in
evaluating the correlation between vitamin D and clinical manifestations is not anyway limited to lupus but has been
raised in other autoimmune conditions [98]. For instance, in two metanalyses lately published, a significant inverse
correlation between serum 25(OH)D3 levels and disease severity has been found in both Crohn’s disease and RA [37,
38].
Table 1. Relevant studies published over the last decade investigating the correlation between vitamin D levels and clinical
and serological manifestations in SLE.
Reference Patients/Ethnicity/Country Main findings
Wang et al, 2017 [99] 113 premenopausal women with SLE (China) 25(OH)D3 lower level associated with increased metabolic
syndrome prevalence, decreased HDL level and higher level of
fasting glucose
Shahin et al, 2017 [100] 57 treatment-naïve SLE and 42 controls (Egypt) 25(OH)D3 lower levels associated with thrombocytopenia, no
other clinical manifestations
Negative correlation between vitamin D and ANA titre, IL-17 and
IL-23
Garcia-Carrasco et al, 2017
[101]
137 women with SLE (Mexico) No association between vitamin D and MEX-SLEDAI
Abdel-Galil et al, 2017 [102] 123 SLE and 100 controls (Egypt) Negative correlation between vitamin D and SLEDAI in the high-
disease activity group and patients with lupus nephritis
Negative correlation between 25(OH)D3 and IFN-α serum
level/gene expression (> in patients with lupus nephritis)
Eloi et al, 2017 [103] 199 SLE patients (Brazil) Negative correlation between vitamin D and SLEDAI
Salman-Monte et al, 2016
[104]
102 female SLE patients (Spain) Negative correlation between vitamin D insufficiency and fatigue
25(OH)D3 lower levels associated with more oral corticosteroids
Gao et al, 2016 [105] 121 SLE patients and 150 controls (China) Severe vitamin D deficiency is prevalent in moderate/high disease
activity (SLEDAI), but no correlation with organ damage (SDI)
Simioni et al, 2016 [106] 153 SLE patients and 85 controls (Brazil) No correlation between vitamin D and SLEDAI
Lower levels of vitamin D associate with leukopenia
Kokic et al, 2016 [107] 22 female SLE patients and 21 controls (Croatia) Negative correlation between vitamin D levels and IFN-γ
Lin et al, 2016 [108] 35 pediatric-onset SLE (in active and inactive
disease states) (Taiwan)
Lower levels of vitamin D associate with lupus nephritis
Significant negative correlation between 25(OH)D3 and
SLEDAI-2k
Yap et al, 2015 [109] 119 SLE patients (Australia) Negative correlation between vitamin D and SLEDAI-2K
Increase in serum 25(OH)D3 associated with reduced disease
activity
Tay et al, 2015 [110] 61 SLE patients and 61 controls (Singapore) 25(OH)D3 lower levels independently predicted cognitive deficit
in lupus patients.
Garf et al, 2015 [111] 70 juvenile-onset SLE patients, 40 controls
(Egypt)
No correlation between vitamin D deficiency and SLEDAI
Dall’Ara et al, 2015 [112] 50 SLE patients, 30 SLE patients during disease
flare; 170 healthy controls (Italy)
Measured 2 values, in winter and summer
Lower vitamin D associated with disease flares during winter
Sabio et al, 2015 [113] 106 non-diabetic female SLE patients and 101
controls (Spain)
25(OH)D3 lower levels associated with insulin resistance and
metabolic syndrome (trend)
Negative correlation between vitamin D and insulin and C3
Sahebari et al, 2014 [114] 82 SLE patients and 49 controls (Iran) No association between vitamin D deficiency and SLEDAI
Schoindre et al, 2014 [115] 170 patients treated with HCQ for 6 months
(Plaquenil LUpus Systemic study) (France)
Negative correlation between 25(OH)D3 and SLEDAI score
No association with flares during the six months following the
measurement
Lertratanakul et al, 2014
[116]
890 patients SLE (North America, Europe and
Asia)
Negative correlation between 25(OH)D3 and SELENA-SLEDAI
score
25(OH)D3 lower levels associated with increased risk for
hypertension and hyperlipidaemia but no correlation with other CV
events
Mandal et al, 2014 [11] 129 SLE patients (79 treatment-naïve, 50
treated), 100 controls (India)
Negative correlation between 25(OH)D3 and SLEDAI, anti-
dsDNA titre, plasma/gene expression of IFNα
Higher levels of plasma IFN-α in treatment-naïve SLE patients
compared to treated patients and controls
McGhie et al, 2014 [117] 75 patients with SLE (Jamaica) Negative correlation between vitamin D and BILAG score (trend)
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Reference Patients/Ethnicity/Country Main findings
De Souza et al, 2014 [118] 45 SLE patients and 24 controls (Brazil) No association between vitamin D deficiency and SLEDAI
25(OH)D3 lower levels associated with higher rate of haematuria
and higher IL-6 level
Jung J et al, 2014 [119] 102 female SLE patients and 52 controls (Korea) No correlation between vitamin D levels and subclinical markers of
atherosclerosis
Abou-Raya et al, 2013 [89] 267 SLE patients (Egypt) 25(OH)D3 lower levels correlated with higher SLE disease activity
(SLEDAI)
Chaiamnuay et al, 2013 [51] 101 SLE patients (Thailand) Inverse correlation between 25(OH)D3 and creatinine levels and
glucocorticoid doses
Attar et al, 2013 [90] 95 SLE patients (Saudi Arabia) 25(OH)D3 lower levels associated with active SLE, azathioprine
treatment, low C3/C4
No correlation between vitamin D and SLEDAI-2K.
25(OH)D3: negative correlation with anti-dsDNA, positive
correlation with C4
Kiani et al, 2013 [120] 200 patients followed up for 2 years
Lupus Atherosclerosis Prevention Study -
Hopkins Lupus Cohort (US)
No association between 25(OH)D levels and subclinical markers of
atherosclerosis
Sumethkul et al, 2012 [42] 108 SLE patients (Thailand) 25(OH)D3 lower levels associated with urinary protein/creatinine
index and nephritis with proteinuria
Mok et al, 2012 [43]
Mok et al, 2012 [46]
290 Chinese patients with SLE (Hong Kong) Negative correlation between 25(OH)D3 levels and SLEDAI
scores and PGA
25(OH)D3 levels significantly lower in patients who experienced
disease flares
25(OH)D3 lower levels associated with higher prevalence of aPL
syndrome and higher total/HDL cholesterol ratio
Negative correlation between 25(OH)D3 levels and anti-C1q/anti-
dsDNA titres
No correlation with complement levels, atherosclerosis, and organ
damage
Yeap et al, 2012 [121] 38 premenopausal SLE (Malaysia) Negative correlation between vitamin D levels and SLEDAI scores
Stockton et al, 2012 [41] 24 SLE 21 controls (Australia) No correlation between vitamin D levels and fatigue
Birmingham et al, 2012 [122] 46 SLE patient (82 flares) (US) 25(OH)D3 levels decreased during flares (especially in non-
African American)
Bogaczewicz et al, 2012
[123]
49 SLE 49 controls (Poland) Vitamin D deficiency associated with renal disease and leukopenia
Munoz-Ortego et al, 2012
[124]
73 SLE (Spain) No correlation between vitamin D and SLEDAI and SLICC/ACR
scores
Fragoso et al, 2012 [125] 78 SLE 64 controls (Brazil) No association between vitamin D and SLEDAI, fatigue and anti-
dsDNA
Reynolds et al, 2012 [126] 75 SLE (United Kingdom) 25(OH)D3 lower levels associated with higher SLEDAI-2K, higher
BMI and insulin resistance
Negative correlation between serum 25(OH)D3 concentration and
aortic stiffness (independent of BMI, insulin and other CVD risk
factors)
No association between vitamin D levels and carotid plaque area
and intima media thickness.
Ravenell et al, 2012 [127] 51 SLE African-American patients Negative correlation between vitamin D and age-adjusted total
plaque area
Hamza et al, 2011 [45] 60 SLE 60 controls (Egypt) Negative correlation between vitamin D levels and SLEDAI scores
25(OH)D3 lower levels associated with higher prevalence of
photosensitivity
Souto et al, 2011 [44] 159 SLE patients (Brazil) No correlation between vitamin D levels and disease activity score
Bonakdar et al, 2011 [128] 40 SLE (Iran) Negative correlation between vitamin D levels and BILAG index
score
25(OH)D3 lower levels associated with higher anti-dsDNA, lower
Hb and albumin concentrations and higher LFTs
Szodoray et al, 2011 [129] 177 SLE (Hungary) Negative correlation between vitamin D levels and SLEDAI score
25(OH)D3: negative correlation with anti-dsDNA, anti-Sm, and
IgG levels; positive correlation with complement levels
25(OH)D3 lower levels associated with higher prevalence of
pericarditis, neuropsychiatric diseases and deep vein thrombosis
(Table ?) contd.....
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Reference Patients/Ethnicity/Country Main findings
Kim et al, 2011 [130] 104 SLE 49 controls (Korea) No association between vitamin D levels and SLEDAI and SLICC
Positive correlation between vitamin D and Hb and serum
complement
Amital et al, 2010 [131] 378 European/Israeli patients Negative correlation between vitamin D and disease activity
(SLEDAI-2K/ ECLAM scales)
Ben-Zvi et al, 2010 [132] 198 SLE patients (US) Negative correlation between vitamin D and disease activity
Ruiz-Irastorza et al, 2010
[133]
80 SLE (Spain) No correlation between vitamin D levels and SLEDAI/SDI
Negative correlation between 25(OH)D3 levels and VAS-fatigue
Toloza et al, 2010 [10] 124 SLE patients (Canada) No correlation between vitamin D and disease activity
Association between vitamin D and creatinine levels
Wu et al, 2009 [134] 181 female SLE (US) Negative correlation between vitamin D levels and SLEDAI and
SLICC scores.
25(OH)D3 lower levels associated with higher diastolic blood
pressure, LDL cholesterol, lipoprotein-a, BMI and insulin
resistance (significance lost if adjusting for BMI)
Borba et al, 2009 [135] 36 SLE, 26 controls (Brazil) Inverse correlation between vitamin D level and SLEDAI,
osteocalcin and bone-specific alkaline phosphatase
Cutolo et al, 2008 [136] SLE patients from Estonia and Italy Negative correlation between 25(OH)D3 levels and ECLAM and
SLEDAI (in all patients)
Thudi et al, 2008 [137] 37 female SLE (US) Vitamin D deficiency associated with lower disease global
assessment scores
Higher dsDNA titres associated with vitamin D > 47.7 nmol/L
Ruiz-Irastorza et al, 2008 [48] 92 SLE patients (Spain) No association between vitamin D levels and disease duration,
disease activity (SLEDAI, SLICC-ACR).
Low vitamin D levels associated with self-rated fatigue VAS score
Orbach et al, 2007 [12] 138 SLE patients No correlation between Vitamin D and ECLAM score
Kamen et al, 2006 [14] 123 recently diagnosed SLE 240 controls (US) 25(OH)D3 lowest levels (<10 ng/ml) associated with renal disease
and photosensitivity
ANA, Anti-Nuclear Antibodies; SLE, Systemic Lupus Erythematosus; SLEDAI, Systemic Lupus Erythematosus
Disease Activity Index; SLEDAI-2K, SLEDAI-2000; BILAG, British Isles Lupus Activity Group; SELENA, Safety of
Estrogens  in  Lupus  Erythematosus  National  Assessment;  ECLAM,  European  Consensus  of  Lupus  Activity
Measurement;  SDI,  Systemic  Lupus  International  Collaborating  Clinics  Damage  Index;  PGA,  Physician  Global
Assessment;  SLICC, Systemic Lupus International  Collaborating Clinics;  aPL, Anti-Phospholipid syndrome; HDL,
High Density Lipoproteins; Hb, Haemoglobin; LFTs, liver function tests; VAS, visual analogue score; BMI, Body Mass
Index; CV, Cardiovascular.
6.1. Vitamin D and SLE Disease Activity
Over the last decade, a considerable number of reports investigated the association between the serum concentration
of vitamin D and the severity of the disease in lupus patients. Unfortunately, heterogeneous indexes have been used for
assessing the disease activity (e.g. SLEDAI, SELENA-SLEDAI, BILAG, ECLAM) making somehow tricky the direct
comparison  between trials.  Independently  of  the  score  used,  a  significant  proportion  of  these  observational  studies
showed the existence of an association between lower 25(OH)D3 serum concentration and higher disease activity [11,
42,  43,  45,  89,  103,  105,  108,  109,  121,  126,  128]  [129,  131,  132,  135,  136].  However,  this  correlation  was  not
confirmed in all the studies [10, 12, 44, 48, 90, 101, 106, 114, 118, 124, 130, 133]. The reasons beyond these discrepant
results might be several; as mentioned, various indexes of disease activity have been used throughout the studies, as not
a  single  standard  measurement  exists.  Moreover,  the  different  ethnicity  of  the  subjects  included  could  also  play  a
substantial role. Despite the evidence of an association between vitamin D levels and disease activity, a direct causal
relationship has not been found yet and cannot be driven as a conclusion from observational studies. On the one hand,
in keeping with the effects of vitamin D/VDR on the immune system, deficit in vitamin D might represent a trigger for
the development of autoimmunity and more aggressive disease. On the other hand, however, 25(OH)D3 concentration
might be lowered secondary to the presence of systemic inflammation. Interestingly, even if a continuous high disease
activity correlates with organ damage, most of the studies failed to show a correlation between low serum 25(OH)D3
and  lupus-related  organ  damage  [105];  in  some  circumstances,  lower  vitamin  D  levels  have  been  associated  with
disease flares [42,  112, 122].  A more consistent consensus has been raised with regards to the negative correlation
between vitamin D and ANA titres [11, 46, 88, 90, 100, 128, 129], in keeping with the in vitro ability of vitamin D of
inhibiting B cells activation and autoantibodies production.
(Table ?) contd.....
234   The Open Rheumatology Journal, 2018, Volume 12 Nerviani et al.
It  is  possible  that  some  confounding  factors  could  drive  the  link  between  low  levels  of  25(OH)D3  and
severity/features  of  the  disease.  A  meta-analysis  published  in  2014  analysed  the  results  of  11  articles  reporting  a
Pearson correlation coefficient between vitamin D levels and disease activity, more than 20 patients and at least one
confounder factor for vitamin D serum concentration. Here the Authors showed that the most commonly identified
confounding factors were renal function, proteinuria, BMI, and concurrent treatment including Disease Modifying Anti-
Rheumatic  Drugs  (DMARDs),  steroids  and  vitamin  D  supplementation  [114].  Among  the  specific  clinical
manifestations lupus-related, nephritis [14, 42, 51, 108, 123] and CV involvement have been the more often associated
with vitamin D deficiency (the correlation with CV manifestations will be discussed in details in the next paragraph).
6.2. Vitamin D and Cardiovascular Disease in Lupus Patients
With regards to CV disease, it  is well accepted that patients affected by SLE have an increased CV risk, which
especially manifests at an earlier age in comparison to the general population and translates into a higher mortality CV-
related [138, 139]. The raised prevalence of CV events can be explained by the contribution of risk factors related to
both the disease itself, such as chronic inflammation, and the disease treatment, including long-term use of steroids,
both in association with traditional CV risk factors (e.g. smoking, hypertension, high low-density lipoprotein levels,
obesity, impaired glucose metabolism) [140]. Accelerated atherosclerosis triggered by traditional and disease-related
risk  factors  such  as  disease  duration,  raised  homocysteine  levels  and  pro-inflammatory  cytokines  [141],  and  the
metabolic syndrome seem to be particularly important, the latter being present in almost half of lupus patients at the
disease onset and being associated with the cumulative damage of organs and tissues [142, 143].
Since in the general population vitamin D deficiency has been described as a risk factor for the occurrence of CV
disease [144 - 146], its association and role in the development of CV disease has also been assessed in the context of
SLE. Once again, even if  data in this field are somehow contradicting, there is substantial  evidence that vitamin D
deficiency associated with CV risk factors in lupus [42, 113, 116, 126, 134, 147, 148]. Some Authors have supported
the  direct  correlation  between  low  vitamin  D  levels  and  the  age-adjusted  total  area  of  the  carotid  plaque  in  lupus
patients [127]. This has not been confirmed in a different study [126], which, nonetheless, highlighted how vitamin D
deficiency  associated  with  increased  aortic  stiffness  [126].  The  relationship  between  low vitamin  D and  metabolic
syndrome  has  been  shown  too  [99].  Evidence  from  observational  studies  prompted  interventional  trials  aiming  at
assessing the value of vitamin D supplementation for controlling/reducing CV risk factors. Results from the Women’s
Health Initiative (including 36282 post-menopausal women) did not support a role for vitamin D in modifying the CV
risk in the general female population; however, the design of the study, which allowed a personal supplementation of
vitamin  D  in  the  untreated  arm  might  have  constituted  a  fundamental  confounding  factor  [149].  A  metanalysis
published  by  Chowdhury  et  al.  in  2014  considering  73  observational  studies  and  22  randomised  controlled  trials
concluded that a negative correlation between vitamin D levels and mortality rate (including for CV-related causes)
exists  in  the general  population and that  the supplementation with 25(OH)D3 can decrease the overall  mortality  in
adults  (average  age  56-85  years  old)  [150].  Thus,  although  in  the  absence  of  robust  lines  of  evidence,  vitamin  D
supplementation is encouraged in lupus patients [151] in keeping with the raised CV risk and related mortality.
6.3. Vitamin D and Fatigue Lupus-Related
Fatigue is one of the most common symptoms described by patients affected by SLE, being present in around 80%
of  all  lupus  patients  and  conferring  disability  in  more  than  half  of  patients  [152].  Vitamin  D  deficiency  has  been
reported in several studies as a factor associated with fatigue in SLE, even when no other clinical correlations were
found [48, 104, 133, 153]. Salman-Monte et al., for instance, have recently shown that non-supplemented SLE female
patients with insufficient vitamin D levels had significantly higher fatigue compared to subjects with normal vitamin D
serum ranges [104]. Moreover, increased 25(OH)D3 levels secondary to supplementation seem to have a favourable
influence  on  fatigue  as  suggested  by  the  significant  inverse  correlation  between  changes  in  vitamin  D  levels  and
differences in the VAS fatigue score post-supplementation [133].
7. VITAMIN D SUPPLEMENTATION IN SLE: GOALS, REGIMENS AND THERAPEUTIC EFFECTS
At the time being, universally accepted guidelines about which categories of patients need to be tested for vitamin D
deficiency  have  not  been  published  yet,  but  recommendations  come  from  diverse  societies  and  organisations.  For
instance, the National Osteoporosis Society (NOS) suggested that only patients with bone or musculoskeletal symptoms
should be tested [154] while the ES advised the measurement of vitamin D for patients affected by obesity, liver and
chronic kidney disease and, more generally, subjects of Hispanic and African-American ancestry [30]. The controversy,
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which was later discussed in two additional reports [155, 156], effectively exemplifies the difficulties in finding an
international  agreement  in  the  field  of  vitamin  D,  already  evident  in  the  discrepancies  of  results  reported  in  the
observational studies listed above.
Similarly to the screening, no worldwide-accepted guidelines currently exist with regards to the supplementation of
vitamin D (target levels and therapeutic regimes) in both the general population and in specific groups of patients, e.g.
SLE. Cholecalciferol is the most common form of vitamin D used for supplementation in routine care [30]. The amount
of vitamin D intake recommended hugely vary according to the different guidelines, from 600 IU/day (only dietary
intake)  advocated  for  the  general  population  by  the  IOM  [157]  to  1500-2000  IU/day  for  subjects  at  high-risk  as
suggested  by  the  ES  [30].  The  NOS  proposed  for  patients  with  values  <  30  nmol/l  a  loading  dose  of  300000  IU
followed  by  a  maintenance  dose  of  800-2000  IU/day  [154].  Conversely,  the  European  Society  for  Clinical  and
Economic  Aspects  of  Osteoporosis  and  Osteoarthritis  recommended  supplementation  of  800  to  1000  IU/day  for
baseline 25(OH)D3 values below 50 nmol/L (20 ng/mL) [158]. A comprehensive metanalysis including 11 randomised
trials  of  vitamin  D  supplementation  concluded  that  treatment  with  ≥  800  IU/day  was  helpful  for  preventing  non-
vertebral fractures in older adults [159], but there is no mention about any potential extra-skeletal effect of vitamin D.
Despite  the  favourable  effects  of  vitamin  D  administration  in  murine  models  of  autoimmunity,  the  efficacy  of
vitamin  D  supplementation  as  an  immunomodulatory  agent  for  treating  lupus  and  other  autoimmune  diseases  is
currently under debate. A conventional therapeutic approach to SLE patients is missing; in routine care, the goal of the
supplementation is the prevention of fractures and the protection of the bone, usually represented by values > 30-40
ng/ml [160]. The adjustment of the dose at individual levels should be made based on specific risk factors, in particular,
the concurrent  use of  steroids in keeping with their  known negative action on vitamin D absorption [33,  161,  162]
[163].  A  large  inception  study  including  223  Spanish  newly  diagnosed  SLE  patients  and  assessing  the  nature  of
treatment during the first  year of follow-up concluded that vitamin D supplementation was below the optimal dose
required [164].
Multiple interventional trials have been performed, but further will be needed to clarify the potential therapeutic
effects of vitamin D in SLE beyond the bone protection. To date, only conventional doses of vitamin D have been used
in trials, aiming to correct the deficiency but not to achieve predefined serum levels. Vitamin D supplementation is
advantageously  very  well  tolerated  and  only  rarely  toxic,  and  complications  associated  to  vitamin  D  toxicity  (e.g.
hypercalcemia, hypercalciuria, calcifications) start appearing when levels are > 80 ng/ml [160]. Though, it would be
interesting to evaluate the effects of higher doses of vitamin D in patients with lupus, trying to reproduce and enhance
the immuno-modulation observed in vitro and animal models. Here, we have listed and discussed the most relevant
interventional trials of vitamin D supplementation in lupus patients.
7.1. Interventional Clinical Trials
A large double-blind randomised controlled trial published in 2013 by Abou-Raya et al. included 267 SLE Egyptian
patients with SLEDAI >1 and serum vitamin D level < 75 nmol/L randomised to receive cholecalciferol 2000 IU/day or
placebo in a 2:1 ratio. At the end of the study (12 months), the SLEDAI was improved in the treatment arm; moreover,
compared to the placebo group,  cholecalciferol-treated patients  had lower anti-dsDNA and inflammatory cytokines
serum levels [89]. In the same year, Petri et al. assessed the effects of vitamin D supplementation in 1006 SLE patients
(Hopkins Lupus Cohort).  Lupus patients  with baseline 25(OH)D3 levels  < 40 ng/mL (around 80% of the recruited
subjects) received 50000 IU/week of ergocalciferol in combination with a total of 400 IU calcium/cholecalciferol daily.
Patients  who  corrected  the  vitamin  D  deficiency  had  a  modest  but  significant  improvement  of  the  disease  activity
measured with the SELENA version of SLEDAI. Moreover, an amelioration of the urine-protein-to-creatinine ratio was
observed too [165]. Ruiz-Irastorza et al. assessed the relationship between vitamin D supplementation and changes in
clinical variables in 60 patients with SLE treated as per routine care for vitamin D deficiency and recruited in a previous
observational study. Despite increasing the concentration of serum vitamin D, a remarkable proportion of patients still
had low levels post-supplementation. The advantageous effect of increasing vitamin D levels was observed in the VAS
fatigue.  However,  no  significant  effects  were  found  on  lupus  disease  activity  or  organ  damage  [133].  Similar
conclusions, i.e. the absence of modifications in disease activity (assessed by SLEDAI) following vitamin D treatment
were drawn in an open-label study enrolling 20 lupus patients and treating them with 100000 IU/weekly for one month
followed by 100000 IU/monthly for six months. On the other hand, anti-dsDNA titres, memory B cells number, and the
percentage  of  Th1/Th17 decreased  while  Treg  increased.  At  the  end of  the  trial,  patients  had  reached significantly
higher levels of vitamin D compared to baseline [85]. In 2015, Aranow et al.  reported the results of a double-blind
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randomised controlled trial evaluating the effects of vitamin D supplementation on the IFN signature response in SLE
patients. 57 lupus patients with baseline vitamin D < 20 ng/ml and stable inactive disease were enrolled. Patients were
required to have the presence of an IFN signature at baseline; this was quantified by gene expression of 3 IFN-related
genes. Patients were randomised in 3 groups to receive 4000 IU/day of cholecalciferol, 2000 IU/day cholecalciferol and
placebo for 12 weeks. At the end of the study, 16/33 patients receiving active treatment replenished vitamin D serum
level,  but  no  significant  IFN-signature  response  was  observed  even  in  patients  who  achieved  adequate  vitamin  D
concentrations. The absence of IFN response might be explained by the relatively short time of the study and by the
disease status  at  baseline (inactive)  [91].  In  another  recent  randomised trial,  34 female lupus patients  received two
different regimens of vitamin D supplementation for a total of 2 years. Patients were supplemented with one of the two
schemes for 12 months and afterwards switched to the second therapeutic strategy. One scheme, standard, consisted of
cholecalciferol 25000 IU/month; the other, more intensive, of 300000 IU initial loading followed by 50000 IU/month.
Overall, the study failed to find clinical efficacy (disease activity and serology) of vitamin D supplementation in lupus
patients independently of the regimen. It showed, however, favourable immunological variations such as enrichment of
the Treg and increased release of Th2 cytokines. Remarkably, only the most intensive regimen allowed the achievement
of adequate levels of vitamin D [86, 166]. The superiority of a high loading dose of cholecalciferol in correcting vitamin
D deficiency  has  been  previously  observed  [167].  In  another  randomised  placebo-controlled  study,  45  Vitamin  D-
deficient  lupus  patients  were  enrolled  and  received  vitamin  D  (50.000  UI/week  for  12  weeks  followed  by  50000
UI/month for three months); additional 45 patients were randomised to receive placebo. Even if the level of vitamin D
significantly increased after the supplementation (but not in the placebo group), there was no difference in the SLEDAI
between the two groups [168].
Lima et  al.  instead confirmed similar  results  as  published by Abou-Raya et  al.  and Petri  et  al.  in  young adults
affected  by  juvenile  SLE.  40  patients  were  enrolled  in  a  placebo-controlled  trial  and  randomised  1:1  to  receive
cholecalciferol 50000 IU/week or placebo for 24 weeks. Vitamin D supplementation significantly improved the disease-
related fatigue; moreover, a significant difference in SLEDAI and ECLAM was reported in favour of the treated group
[169]. The beneficial effects of vitamin D on juvenile-onset SLE patients have also been established in the study of
AlSaleem  et  al.  in  which  28  children  (24  with  low  vitamin  D  levels)  with  lupus  were  recruited  and  received
cholecalciferol 2000 IU/daily. After 12 weeks, a significant proportion of patients had improvement in SLEDAI score
and autoantibodies titres [170].
The influence of vitamin D supplementation on the endothelial function, known to be impaired in patients with SLE
[171], was evaluated in a pilot case-control study recently published by Kamen et al. Lupus patients vitamin D-deficient
were randomised to receive oral vitamin D supplementation or placebo. In the absence of replenishment of the vitamin
D levels (not reaching ≥32 ng/mL), the Flow-Mediated-Dilation (FMD), which is an indirect measure of the endothelial
function, did not improve. Contrariwise, around 50% of the patients who increased vitamin D concentration had better
values  of  FMD  by  the  end  of  the  trial  [172].  Furthermore,  in  vitamin  D-deficient  patients  treated  with  oral
supplementation, a positive correlation between the improvement of the FMD values and the change in the vitamin
levels post-treatment was proved [173]. Overall, these positive results call further larger studies assessing this aspect in
lupus patients.
The potential favourable action of vitamin D supplementation on the endothelial function is not disease-specific; in
fact, a single high dose of oral vitamin D was able to significantly improve FMD values in patients affected by type 2
diabetes mellitus in comparison with healthy controls [174]. Ex vivo studies corroborated the possible vitamin D ability
of positively enhancing the endothelial repair mechanisms and the global endothelial function [173, 175], for example
by reducing the NETosis [79].  Studies in experimental  models of  SLE (MRL/lpr)  also showed that  lower levels  of
vitamin D correlated with impaired endothelium-dependent vasodilation and defective neoangiogenesis in agreement
with the human findings [176].
7.2. Conclusive Remarks on Interventional Trials
Overall, drawing definitive conclusions from the interventional studies discussed above is still not feasible because
of the controversies of the results. Several reasons can explain the disagreement between findings: the limited number
of  patients  included  in  some  trials;  a  still  relatively  low  number  of  double-blind  randomised  controlled  trials;  the
heterogeneous  features  of  patients  enrolled  (e.g.,  different  baseline  vitamin  D  levels,  various  disease  activity,
concomitant  treatment);  and  a  non-univocal  treatment  regimen  (dose/duration/final  goal).
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The central open question remains whether or not vitamin D might constitute a valuable therapeutic approach in
modulating the immune response and the clinical/serological manifestations of lupus, potentially acting as sparing agent
for other more harmful medications currently in use. Numerous revisions of the literature have been lately published,
but rarely the Authors reached an incontrovertible consensus towards one or other conclusions [33, 40]. It is plausible
that the lack of clinical effects vitamin D-related in some studies lies in an inadequate therapeutic approach regarding
the dose, the duration and the patients’ selection. Since it has been observed that patients with autoimmune diseases
have persistently  raised values  of  PTH,  it  is  likely  though that  the  goal  of  the  supplementation should be  the  PTH
suppression and not  a  “target”  vitamin D plasmatic  concentration [177].  The increasing interest  for  the therapeutic
utility of vitamin D supplementation in the prevention and management of pathologic conditions is not limited to lupus
but also involves other major chronic diseases, both autoimmune and not (type 1 diabetes, multiple sclerosis, and CV
disorders) [178]. In conclusion, the promising results reported in some studies [89, 165] need to be confirmed, and
further large clinical trials are therefore warranted in this field.
CONCLUSIONS AND TAKE HOME MESSAGES
Patients  with  SLE are  more  prone  to  be  vitamin  D  deficient  compared  to  the  general  population;  however,1.
vitamin D deficiency is common also in healthy individuals.
Potential  determinants  of  vitamin  D  deficiency  in  SLE  include  reduced  UV  exposure,  genetic  variations,2.
corticosteroid treatment, and renal disease.
Current knowledge is not conclusive with regards to the role of vitamin D deficiency in the development of3.
autoimmunity and, specifically, SLE. Increased risk of SLE associates with polymorphisms of the VDR; higher
incidence of vitamin D deficiency in ANA-positive non-lupus subjects and siblings of lupus patients (high-risk
subjects) are in favour a causal relationship, but this has not been confirmed yet.
Immune cells express VDRs ubiquitously. Overall, vitamin D up-regulates anti-inflammatory responses, a shift4.
towards  Treg and Th2,  reduced B cells  activation and Ig  production (including anti-dsDNA),  and enhanced
tolerogenicity of dendritic cells. In experimental models of lupus, vitamin D supplementation can improve the
disease.
Numerous  observational  studies  have  investigated  the  correlation  between  vitamin  D  levels  and5.
clinical/serological manifestations of lupus with contrasting results. A negative relationship between vitamin D
levels and disease activity, renal disease, CV risk factors and complications, fatigue, and anti-dsDNA titres have
been described but not conclusively accepted.
Several interventional studies have tried to define the therapeutic value of vitamin D supplementation on disease6.
activity,  renal  function,  CV  risk,  fatigue,  immunological  profiles,  and  IFN-signature,  however,  once  again,
drawing controversial conclusions. Further large clinical trials with well-defined therapeutic protocols and goals
are warranted to shed light on this topic.
LIST OF ABBREVIATIONS
ANA = Anti-Nuclear Antibodies
aPL = Anti-Phospholipid syndrome
BILAG = British Isles Lupus Activity Group
BMD = Bone Mineral Density
BMI = Body Mass Index
CTD = Connective Tissue Disease
CV = Cardiovascular
CYP = Cytochrome p450
DCs = Dendritic Cells
DMARDs = Disease Modifying Anti-Rheumatic Drugs
ds = Double-strand
ECLAM = European Consensus of Lupus Activity Measurement
ES = Endocrine Society
FGF = Fibroblast-Growth-Factor
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FMD = Flow-Mediated-Dilation
Hb = Haemoglobin
HDL = High Density Lipoproteins




IOM = Institute of Medicine
LFTs = Liver Function Tests
NET = Neutrophils-Extracellular-Traps
NK = Natural Killer
NOS = National Osteoporosis Society
PGA = Physician Global Assessment
PTH = Parathyroid Hormone
RA = Rheumatoid Arthritis
SDI = Systemic Lupus International Collaborating Clinics Damage Index
SELENA = Safety of Estrogens in Lupus Erythematosus National Assessment
SLE = Systemic lupus erythematosus
SLEDAI = Systemic Lupus Erythematosus Disease Activity Index
SLICC = Systemic Lupus International Collaborating Clinics
SNPs = Single Nucleotide Polymorphisms
TCR = T-Cell Receptor
Th = T Helper
TNF = Tumor Necrosis Factor
TLR = Toll-Like-Receptors
Treg = T regulatory
UV = Ultraviolet
VAS = Visual Analogue Score
VDRs = Vitamin D Receptors
VDREs = Vitamin D Response Elements
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